Cel-Sci Corp ( CVM ) - 1 Jahr vor dem "Start", der neue Thread (Seite 80)
eröffnet am 10.02.15 23:59:46 von
neuester Beitrag 18.05.24 15:35:12 von
neuester Beitrag 18.05.24 15:35:12 von
Beiträge: 844
ID: 1.207.442
ID: 1.207.442
Aufrufe heute: 3
Gesamt: 108.414
Gesamt: 108.414
Aktive User: 0
ISIN: US1508376076 · WKN: A2DY0D · Symbol: LSRM
1,2140
EUR
+1,51 %
+0,0180 EUR
Letzter Kurs 14:18:54 Tradegate
Neuigkeiten
14.02.24 · dpa-AFX |
05.12.23 · dpa-AFX |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0400 | +46,48 | |
| 1,1400 | +30,85 | |
| 2,7700 | +25,91 | |
| 8,2000 | +16,31 | |
| 1,4800 | +12,98 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,9000 | -15,70 | |
| 3,1000 | -15,76 | |
| 2,3100 | -16,61 | |
| 4,2300 | -18,65 | |
| 5,0000 | -37,34 |
Beitrag zu dieser Diskussion schreiben
FeedbackCEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand http://www.wallstreet-online.de/nachricht/7703454-cel-sci-is…
Zahl der Einschreibungen für Mai
http://www.wallstreet-online.de/nachricht/7683268-cel-sci-re…Einschreibungen 2015:
(2.2.15) - 24 Probanten im Januar
(3.3.15) - 25 Probanten im Februar - Schlusskurs 1,14 USD
(1.4.15) - 29 Probanten im März - Schlusskurs 1,04 USD
(1.5.15) - 31 Probanten im April - Schlusskurs ??? USD
(1.6.15) - 26 Probanten im Mai - Schlusskurs 0,75 USD
Stand 31.05.15 gesamt 463 Probanten
Plan 880 Patienten in 100 Centren in ca 25 Ländern bis 1 Quartal 2016 ( ehemals Ende 2015
Mit der aktuellen Meldung revidiert CVM seinen Zeitplan. Wie vor einiger Zeit von mir vermutet, wir als Termin nun auch das 1 Quat 2016 benannt. Ich hatte ursprünglich noch mit Januar gerechnet
With over half of patients enrolled, we have reached a milestone, as we look forward to completing enrollment by the first quarter of 2016 Noch zur Erinnerung: am 22.6.15 ist Annual Meeting of Stockholders
lg ein etwas entäuschter Plaste
Antwort auf Beitrag Nr.: 49.900.498 von Plaste am 02.06.15 23:59:17
Zitat von Plaste: http://www.wallstreet-online.de/nachricht/7678369-cel-sci-an…
Ob es ein Erfolg war, ist fraglich. So wie ich das sehe hatte man wohl etwas Schwierigkeiten die Menge zu platzieren. Die 35 Mio USD vor einigen Wochen fanden ja auch keinen Abnehmer.
20,253,164 shares of common stock and 20,253,164 warrants to purchase shares of common stock. The common stock and warrants were sold at a combined price of $0.79 per unit of securities and resulted in aggregate gross proceeds of $16 million
Nun wurden also 20.253.164 Aktien + 20.253.164 Optionen für gesamt 16 Mio USD bzw. 0,79 USD/ Aktie + Option ausgegeben.
Für mich kein Erfolg.
Antwort auf Beitrag Nr.: 49.900.498 von Plaste am 02.06.15 23:59:17Nun wurden also 20.253.164 Aktien + 20.253.164 Optionen für gesamt 16 Mio USD bzw. 0,79 USD/ Aktie ausgegeben.
sollte heißen:
.... bzw. 0,79 USD/ Aktie + Option ausgegeben
sollte heißen:
.... bzw. 0,79 USD/ Aktie + Option ausgegeben
KE platziert
http://www.wallstreet-online.de/nachricht/7678369-cel-sci-an…Ob es ein Erfolg war, ist fraglich. So wie ich das sehe hatte man wohl etwas Schwierigkeiten die Menge zu platzieren. Die 35 Mio USD vor einigen Wochen fanden ja auch keinen Abnehmer.
20,253,164 shares of common stock and 20,253,164 warrants to purchase shares of common stock. The common stock and warrants were sold at a combined price of $0.79 per unit of securities and resulted in aggregate gross proceeds of $16 million
Nun wurden also 20.253.164 Aktien + 20.253.164 Optionen für gesamt 16 Mio USD bzw. 0,79 USD/ Aktie ausgegeben.
Für mich kein Erfolg.
Trading Spotlight
News am laufenden Bande
Kapitalerhöhung – Meldung vom 06.05.15CEL-SCI Announces Proposed Public Offering of Common Stock
http://www.wallstreet-online.de/nachricht/7603425-cel-sci-an…
Zahlen für das 2. Quartal – Meldung vom 8.5.15CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results
http://www.wallstreet-online.de/nachricht/7616853-cel-sci-co…
11.5.15 CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain http://www.wallstreet-online.de/nachricht/7621734-cel-sci-re…
13.5.15 CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italyhttp://www.wallstreet-online.de/nachricht/7637868-cel-sci-re…
22.5.15 CEL-SCI Prices up to $16 Million Public Offering of Common Stock and Warrantshttp://www.wallstreet-online.de/nachricht/7663784-cel-sci-pr…
-------------------------------------------------------------------
Kurze Bemerkungen von mir:
Wie ich das sehe konnte die KE am 06.05.15 nicht platziert werden und eine neue wurde am 22.5.15 begonnen. Solange diese nicht beendet ist steht der Kurs weiterhin unter Druck.
Ich denke aber nach der KE sollte der Kurs ENDLICH einmal anziehen.
Im Yahoo Board gab es ein Gerücht, das die Einschreibungen angeblich sehr sehr gut laufen sollen. Ich persönlich würde darauf nichts geben. Wenn dem so wäre würde es bestimmt bald eine Meldung geben.
Ich versuche auch noch raus zufinden, was mit der Schiedsgerichtsverhandlung ist. Sollte diese nicht Anfang des Monats sein???
Übringens, Anfang nächster Woche kommen die nächsten Zahlen für die Einschreibungen. Hoffen wir, das die Gerüchte sich bewahrheiten.
2015 Annual Meeting of Stockholders – Termin 22.06.2015 http://cel-sci.com/annual_meeting.html ( Termin hiermit von mir berichtigt )
Einschreibungen 2015:
(2.2.15) - 24 Probanten im Januar
(3.3.15) - 25 Probanten im Februar - Schlusskurs 1,14 USD
(1.4.15) - 29 Probanten im März - Schlusskurs 1,04 USD
(1.5.15) - 31 Probanten im April - Schlusskurs ??? USD
Stand 30.04.15 gesamt 437 Probanten
Plan 880 Patienten in 100 Centren in ca 25 Ländern bis Ende 2015
LG an alle Plaste
Nachrichtenquelle: Business Wire (engl.) 01.05.2015, 14:00
CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE MKT: CVM) today announced that in April it enrolled 31 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). April marks the 4th consecutive month of record enrollment for CEL-SCI this year following January, February and March, 2015. Enrollment was 24 patients in January, 25 patients in February and 29 patients in March. Four hundred thirty-seven (437) patients have been enrolled in the Phase III study as of April 30, 2015.
"We are very pleased with the enrollment, particularly since there were major holidays this month that made enrollment much more difficult," stated CEL-SCI Chief Executive Officer Geert Kersten.
About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.
About Multikine
Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. The trial is expected to expand into a total of approximately 100 clinical centers in about 25 countries.
Multikine is also being tested in a Phase I study under a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women. CEL-SCI has entered into two co-development agreements with Ergomed to further the development of Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen plus SOC as compared to subjects treated with current SOC only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA.
CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated", "plans" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K/A for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE MKT: CVM) today announced that in April it enrolled 31 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). April marks the 4th consecutive month of record enrollment for CEL-SCI this year following January, February and March, 2015. Enrollment was 24 patients in January, 25 patients in February and 29 patients in March. Four hundred thirty-seven (437) patients have been enrolled in the Phase III study as of April 30, 2015.
"We are very pleased with the enrollment, particularly since there were major holidays this month that made enrollment much more difficult," stated CEL-SCI Chief Executive Officer Geert Kersten.
About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.
About Multikine
Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. The trial is expected to expand into a total of approximately 100 clinical centers in about 25 countries.
Multikine is also being tested in a Phase I study under a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women. CEL-SCI has entered into two co-development agreements with Ergomed to further the development of Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen plus SOC as compared to subjects treated with current SOC only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA.
CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated", "plans" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K/A for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Einschreibungen 2015:
(2.2.15) - 24 Probanten im Januar
(3.3.15) - 25 Probanten im Februar - Schlusskurs 1,14 USD
(1.3.15) - 29 Probanten im März - Schlusskurs 1,04 USD
Stand 01.04.15 gesamt 406 Probanten
Plan 880 Patienten in 100 Centren in 25 Ländern bis Ende 2015
Wie ich bereits sagte, kann ich mir vorstellen das im 1. Quartal 2016 auch noch eingeschrieben wird um die 880 Probanten zu erreichen. Dieses hatte GK bei seinem letzten Interview auch geäußert. Es könnte aber auch anders laufen. Anscheinend steigen die Zahlen von Monat zu Monat ...
Schade das der Kurs der Entwicklung nicht folgt.
(2.2.15) - 24 Probanten im Januar
(3.3.15) - 25 Probanten im Februar - Schlusskurs 1,14 USD
(1.3.15) - 29 Probanten im März - Schlusskurs 1,04 USD
Stand 01.04.15 gesamt 406 Probanten
Plan 880 Patienten in 100 Centren in 25 Ländern bis Ende 2015
Wie ich bereits sagte, kann ich mir vorstellen das im 1. Quartal 2016 auch noch eingeschrieben wird um die 880 Probanten zu erreichen. Dieses hatte GK bei seinem letzten Interview auch geäußert. Es könnte aber auch anders laufen. Anscheinend steigen die Zahlen von Monat zu Monat ...
Schade das der Kurs der Entwicklung nicht folgt.
3rd CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015
CEL-SCI REPORTS 3rd CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015 FOR ITS PHASE III HEAD AND NECK CANCER TRIALOver 400 patients enrolled in trial as of March 31st
Vienna, VA, April 1, 2015 - CEL-SCI Corporation (NYSE MKT: CVM) today announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for itsinvestigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). March marks the third consecutive month of record enrollment for CEL-SCI this year following January and February, 2015. 406 patients have been enrolled in the Phase III study as of March 31, 2015.
"The accelerating pace of enrollment in our trial is very good. We expect to see continued increases in monthly patient enrollment throughout the year as new clinical centers are added and as existing centers gain more experience with Multikine," stated CEL-SCI Chief Executive Officer Geert Kersten.
About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.
About Multikine
Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. CEL-SCI's Clinical Research Organization, who runs the study for CEL-SCI, is aiming to complete enrollment of about 880 patients to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in over 25 countries.
In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compared to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA (Cooperative Research and Development Agreement).
CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approvedfor sale, barter or exchangeby the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated", "plans" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
...................
Durchsuchen
Cel-Sci Corp ( CVM ) - 1 Jahr vor dem "Start", der neue Thread
